Skip to contentS
Sigyn Therapeutics, Inc.
S
SIGYSigyn Therapeutics, Inc. Q2 2022 · 10-Q
Revenue—
Net Income-$666.33K-$666.33KN/M vs Q2 2021 EPS Diluted-$0.02-$0.02N/M vs Q2 2021 Operating Income-$532,795N/M Operating Cash Flowderived-$394,737N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
ended Jun 30, 2022 · filed Aug 15, 2022 · 46 d after period end